<menu id="ssssw"><table id="ssssw"></table></menu>
  • <rt id="ssssw"><samp id="ssssw"></samp></rt>
  • <bdo id="ssssw"></bdo>
  • Your Good Partner in Biology Research

    Human C4 binding protein,C4BP ELISA Kit

    • 中文名稱:
      人C4結合蛋白(C4BP)ELISA Kit
    • 貨號:
    • 規格:
    • 價格:
    • 其他:


    • 產品描述:

      This Human C4BPA ELISA Kit was designed for the quantitative measurement of Human C4BPA protein in serum, plasma. It is a Sandwich ELISA kit, its detection range is 39 ng/ml - 2500 ng/ml and the sensitivity is 9.75 ng/mL .

    • 別名:
      C4b-binding protein alpha chain ELISA Kit; C4bp ELISA Kit; C4bpa ELISA Kit; C4BPA_HUMAN ELISA Kit; Complement component 4 binding protein alpha ELISA Kit; Complement component 4 binding protein ELISA Kit; Proline-rich protein ELISA Kit; PrP ELISA Kit; RP11-164O23.4 ELISA Kit
    • 縮寫:
    • Uniprot No.:
    • 種屬:
      Homo sapiens (Human)
    • 樣本類型:
      serum, plasma
    • 檢測范圍:
      39 ng/ml - 2500 ng/ml
    • 靈敏度:
      9.75 ng/mL
    • 反應時間:
    • 樣本體積:
    • 檢測波長:
      450 nm
    • 研究領域:
    • 測定原理:
    • 測定方法:
    • 說明書:
    • 精密度:
      Intra-assay Precision (Precision within an assay): CV%<8%      
      Three samples of known concentration were tested twenty times on one plate to assess.  
      Inter-assay Precision (Precision between assays): CV%<10%      
      Three samples of known concentration were tested in twenty assays to assess.    
    • 線性度:
      To assess the linearity of the assay, samples were spiked with high concentrations of human C4BP in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
        Sample Serum(n=4)  
      1:1 Average % 92  
      Range % 87-96  
      1:2 Average % 95  
      Range % 90-99  
      1:4 Average % 90  
      Range % 85-96  
      1:8 Average % 93  
      Range % 89-98  
    • 回收率:
      The recovery of human C4BP spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
      Sample Type Average % Recovery Range  
      Serum (n=5) 98 94-103  
      EDTA plasma (n=4) 89 82-95  
    • 標準曲線:
      These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
      ng/ml OD1 OD2 Average Corrected  
      40 2.931 2.812 2.872 2.736  
      20 2.457 2.349 2.403 2.267  
      10 1.678 1.628 1.653 1.517  
      5 0.860 0.816 0.838 0.702  
      2.5 0.490 0.467 0.479 0.343  
      1.25 0.321 0.317 0.319 0.183  
      0.625 0.199 0.189 0.194 0.058  
      0 0.141 0.131 0.136    
    • 數據處理:
    • 貨期:
      3-5 working days



    • 功能:
      Controls the classical pathway of complement activation. It binds as a cofactor to C3b/C4b inactivator (C3bINA), which then hydrolyzes the complement fragment C4b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment C2a. Alpha chain binds C4b. It interacts also with anticoagulant protein S and with serum amyloid P component.
    • 基因功能參考文獻:
      1. The rs73079108 polymorphism in the 5' upstream region of C4BPA was associated with EH, and rs73079108A may be an independent predictor. PMID: 28627632
      2. INDEED also identified some candidates previously reported to be relevant to HCC, such as intercellular adhesion molecule 2 (ICAM2) and c4b-binding protein alpha chain (C4BPA), which were missed by both Differential expression and differential network analyses PMID: 27592383
      3. Exposure to arterial blood pressure leads to a transient presence of C4bp in the saphenous vein wall. PMID: 28163174
      4. Proteomics study showed a strong association of FN1, A2M, C4BPA and CFB in molecular subtypes of breast cancer, in which, C4BPA and A2M demonstrated a potent signature in blood plasma and tissue samples of Luminal-B (LB) and Triple-negative (TN)subtypes in BC patients, respectively. PMID: 27498393
      5. genetic polymorphism is associated with spontaneous abortion; review PMID: 26658464
      6. whereas the presence of plasminogen did not affect the factor I cofactor activity of C4BP, the activation of plasminogen by urokinase-type plasminogen activator to active plasmin was significantly augmented in the presence of C4BP. PMID: 26067271
      7. C4BPB/C4BPA may not confer susceptibility to schizophrenia among Han Chinese PMID: 25660618
      8. these data suggest that when C4BP is bound to Ail, fI can cleave and inactivate C4b that has bound covalently to bacterial surface structures as well as C4b bound noncovalently to Ail. PMID: 24760758
      9. In patients treated with tacrolimus and mycophenolate mophetil as a maintenance immunosuppression, the lower C4d urinary excretion in early post-transplant period seems to be a low significance prognostic marker of a better long-term kidney outcome. PMID: 24779215
      10. mutations in women experiencing recurrent miscarriages PMID: 23508668
      11. The heptameric core structure is stabilized by intermolecular disulfide bonds. PMID: 23274142
      12. C4BP alpha7beta0 isoform complement control protein-6 domain of C4BP alpha-chain is necessary for tolerogenic activity of the acute-phase C4BPbeta chain. PMID: 23390292
      13. The Lsa30 (LIC110870) is a novel adhesin that binds plasminogen and the complement regulator C4bp. PMID: 22732096
      14. Human pneumococcal glycolytic enzyme enolase, a nonclassical cell surface and plasminogen-binding protein, is a pneumococcal C4BP-binding protein. PMID: 22925928
      15. NC4 Domain of cartilage-specific collagen IX inhibits complement directly due to attenuation of membrane attack formation and indirectly through binding and enhancing activity of complement inhibitors C4B-binding protein and factor H. PMID: 21659506
      16. C4BP is recruited to the S. aureus surface where it functions to inhibit C4 complement effectors, suggesting a previously undescribed immune evasion strategy for this pathogen. PMID: 22333221
      17. Human pentraxin 3 binds to the complement regulator c4b-binding protein. PMID: 21915248
      18. Serum C4BP level in 89 patients showed a strong association with the clinical staging of non small cell lung carcinoma. PMID: 21262398
      19. C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. PMID: 20212171
      20. Binding of the classical pathway inhibitor, C4b-binding protein (C4bp), to three genospecies of B. burgdorferi sensu lato, is demonstrated. PMID: 20022381
      21. Data show that C4BP does not bind CD40, but it forms stable high molecular weight complexes with soluble CD40 ligand (sCD154). PMID: 17225862
      22. structural requirements for the intracellular subunit polymerization PMID: 12135356
      23. Localization of binding sites for a number of C4BP ligands in relation to well-established and novel functions of C4BP. Review PMID: 15179322
      24. To determine the regions of C4b contributing to C4BP binding, the binding of the C4c and C4dg subfragments of C4b to C4BP was examined. PMID: 16819837
      25. Non-small cell lung cancer (NSCLC) cells produce soluble complement inhibitors factor I (FI) and C4b-binding protein (C4BP). PMID: 17548110
      26. The binding sites to Neisseria gonorrhoeae Por1A protein have been mapped within complement control protein domain 1 of C4BP. PMID: 17579075
      27. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. PMID: 18424762
      28. C4BP binds to dead brain cells and Abeta peptide in vitro, is present in CSF and possibly protects against excessive complement activation in AD brains. PMID: 18556068
      29. These results reinforce the case for the occupation of some of the seven arms of C4BP in a multivalent interaction with DNA or surface bound glycosaminoglycans while other arms engage C4b or C3b. PMID: 18715646
      30. Mainly the central core of C4BP mediates binding to small leucine-rich repeat proteins (SLRPs). Binding of SLRPs to C4BP does not not affect its ability to inhibit complement. PMID: 19155499
      31. isoforms of a group B streptococcus-secreted component named Fib displayed differential binding capacities for fibronectin, fibrinogen, and C4BP PMID: 19417080
      32. C4BP binding varies between strains but is dependent on the expression of pneumococcal surface protein C, PspC of group 4 PMID: 19494311
      33. The primary binding site on C4bp is located on the alpha-chain complement control protein 4 (CCP4) domain which, unlike C4bp alpha-chain amino-terminal CCP1 and CCP2, is not involved in complement regulatory activity. PMID: 11441101



    • 亞細胞定位:
    • 組織特異性:
      Chylomicrons in the plasma.
    • 數據庫鏈接:

      HGNC: 1325

      OMIM: 120830

      KEGG: hsa:722

      STRING: 9606.ENSP00000356037

      UniGene: Hs.1012

    <menu id="ssssw"><table id="ssssw"></table></menu>
  • <rt id="ssssw"><samp id="ssssw"></samp></rt>
  • <bdo id="ssssw"></bdo>